Identifying the Predictive Role of Oxidative Stress Genes in the Prognosis of Glioma Patients

27 November 2021: Database Analysis

Di Lu ^12BCDE , Ning Yang ^12BEF , Shuai Wang ^12CDE , Wenyu Liu ^12CD , Di Zhang ^12AF , Jian Wang ^123AG , Bin Huang ^12AE* , Xingang Li ^12AG*

DOI: 10.12659/MSM.934161

Med Sci Monit 2021; 27:e934161

Table 2 Clinicopathological parameters of 686 glioma patients in the CGGA database.

Parameters	Cases	Proportion (%)

0–20	21	3.06
21–40	266	38.78
41–60	341	49.71
61–80	58	8.45

Male	399	58.16
Female	287	41.84

WHO II	177	25.80
WHO III	226	32.94
WHO IV	283	41.25

A	108	15.74
AA	160	23.32
AO	61	8.89
O	74	10.79
GBM	283	41.25

Primary	442	64.43
Recurrent	218	31.78
Secondary	26	3.79

TMZ-treated	501	73.03
Untreated	185	26.97

Treated	544	79.30
Untreated	142	20.70

Mutant	371	54.08
Wild-type	315	45.92

Codeletion	141	20.55
Non-codeletion	545	79.45

Methylated	386	56.27
Unmethylated	300	43.73
GBM – glioblastoma multiforme; TMZ – temozolomide; WHO – World Health Organization.